Myopia Induced after Systemic Chemotherapy with Docetaxel
Journal of Ophthalmic and Optometric Sciences · 15.06.2025
DOI: 10.22037/joos.v8i4.48648 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Ophthalmic and Optometric Sciences, erschienen am 15.06.2025. Verfasst von Azam Abdollahi und 1 weiteren Autor:innen.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Transient myopia is an unreported toxicity of docetaxel. We report an unexpected development of myopia following systemic chemotherapy with docetaxel. A 38-year-old woman undergoing chemotherapy for breast cancer received docetaxel every two weeks. Prior to chemotherapy, she had no visual impairments, ocular disorders, or other comorbidities. After seven cycles of systemic chemotherapy, she began experiencing visual impairment. Her spherical equivalent refractive errors were -2.00 D in the right eye and -1.63 D in the left eye. Uncorrected visual acuity was 0.42 logMAR in the right eye and 0.3 logMAR in the left eye, both correctable to 0 logMAR. At a 4-week follow-up after cessation of chemotherapy, her vision gradually recovered. To our knowledge this is the first reported case of docetaxel induced myopia in a patient undergoing cancer treatment in the English literature, underscoring the need for clinicians to be aware of this potential ocular toxicity.
Schlagwörter
Zitieren
APA
Abdollahi, A., & Tabatabaeefar, M. (2025). Myopia Induced after Systemic Chemotherapy with Docetaxel. Journal of Ophthalmic and Optometric Sciences. https://doi.org/10.22037/joos.v8i4.48648
Vancouver
Abdollahi A, Tabatabaeefar M. Myopia Induced after Systemic Chemotherapy with Docetaxel. Journal of Ophthalmic and Optometric Sciences. 2025. doi:10.22037/joos.v8i4.48648
BibTeX
@article{Abdollahi2025,
author = {Abdollahi, Azam and Tabatabaeefar, Morteza},
title = {Myopia Induced after Systemic Chemotherapy with Docetaxel},
journal = {Journal of Ophthalmic and Optometric Sciences},
year = {2025},
doi = {10.22037/joos.v8i4.48648}
}
EUVIMED